Indication

Aggressive systemic mastocytosis

Aggressive systemic mastocytosis is a rare, severe subtype of advanced systemic mastocytosis characterized by the uncontrolled clonal proliferation and infiltration of neoplastic mast cells into extracutaneous organ systems. Read more about Aggressive systemic mastocytosis

31 drugs 28 manufacturers

Advertisement

Drugs that treat it

Common Aggressive systemic mastocytosis therapies.

Showing 10–18 of 31 drugs

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
DR.REDDY'S LAB

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
ASCEND LABORATO

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
Hikma Pharmaceuticals USA

IMATINIB (imatinib mesylate)

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
ARMAS PHARMACEU

AYVAKIT (avapritinib)

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·AGGRESSIVE SYSTEMIC MASTOCYTOSIS·+3
BLUEPRINT MEDICINES

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
AREVA PHARMACEU
Filter & compare in the drug finder →Opens the drug finder with Aggressive systemic mastocytosis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Aggressive systemic mastocytosis.

Aggressive systemic mastocytosis is a rare, severe subtype of advanced systemic mastocytosis characterized by the uncontrolled clonal proliferation and infiltration of neoplastic mast cells into extracutaneous organ systems.

Predominantly affecting adults, the disorder is driven in most cases by activating mutations in the *KIT* gene (commonly *KIT* D816V).

It is pathophysiologically defined by mast-cell-mediated tissue infiltration that causes clinically evident, non-hematologic organ damage—termed C-findings—such as cytopenias from bone marrow failure, hepatomegaly with liver dysfunction or ascites, portal hypertension, splenomegaly with hypersplenism, malabsorption, and osteolytic bone lesions with skeletal fractures.

Unlike other advanced mast cell disorders, it manifests severe, progressive organopathy without fulfilling the diagnostic criteria for mast cell leukemia or an associated hematologic neoplasm.

Personalize your experience

Follow Aggressive systemic mastocytosis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it